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Patients with chronic kidney disease (CKD) are at increased risk for the development of cardiovascular disease (CVD) 
beyond traditional risk factors. Yet the mechanism(s) through 
which CKD is linked to enhanced atherosclerotic heart disease 
is not fully elucidated. Although a role for uremic toxins in the 
pathogenesis of cardiovascular and renal disease progression 
in CKD has been suggested for some time, the precise partici-
pants involved, and their mechanisms of action remain unclear. 
Recent studies have suggested involvement of gut-microbiota 
in the generation of metabolites that display uremic toxic-
ity.1 Furthermore, perturbations of the composition of the gut 
microbial community in both human and experimental CKD 
are associated with significant elevations of gut-derived ure-
mic toxins.2 Such alterations have also been associated with in-
creased systemic inflammatory burden, and thus are suspected 
to play a role in the pathogenesis of cardiovascular and renal 
disease progression in subjects with CKD. Bacterial structural 
components, such as lipopolysaccharide,3 and metabolites, 
such as indoxyl sulfate, p-cresyl sulfate, amines, and ammonia, 
Rationale: Trimethylamine-N-oxide (TMAO), a gut microbial-dependent metabolite of dietary choline, 
phosphatidylcholine (lecithin), and  l-carnitine, is elevated in chronic kidney diseases (CKD) and associated with 
coronary artery disease pathogenesis.
Objective: To both investigate the clinical prognostic value of TMAO in subjects with versus without CKD, and 
test the hypothesis that TMAO plays a direct contributory role in the development and progression of renal 
dysfunction.
Methods and Results: We first examined the relationship between fasting plasma TMAO and all-cause mortality 
over 5-year follow-up in 521 stable subjects with CKD (estimated glomerular filtration rate, <60 mL/min per 
1.73 m2). Median TMAO level among CKD subjects was 7.9 μmol/L (interquartile range, 5.2–12.4 μmol/L), which 
was markedly higher (P<0.001) than in non-CKD subjects (n=3166). Within CKD subjects, higher (fourth versus first 
quartile) plasma TMAO level was associated with a 2.8-fold increased mortality risk. After adjustments for traditional 
risk factors, high-sensitivity C-reactive protein, estimated glomerular filtration rate, elevated TMAO levels remained 
predictive of 5-year mortality risk (hazard ratio, 1.93; 95% confidence interval, 1.13–3.29; P<0.05). TMAO provided 
significant incremental prognostic value (net reclassification index, 17.26%; P<0.001 and differences in area under 
receiver operator characteristic curve, 63.26% versus 65.95%; P=0.036). Among non-CKD subjects, elevated TMAO 
levels portend poorer prognosis within cohorts of high and low cystatin C. In animal models, elevated dietary choline 
or TMAO directly led to progressive renal tubulointerstitial fibrosis and dysfunction.
Conclusions: Plasma TMAO levels are both elevated in patients with CKD and portend poorer long-term survival. 
Chronic dietary exposures that increase TMAO directly contributes to progressive renal fibrosis and dysfunction 
in animal models. 
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have been identified as potential microbial by-products ca-
pable of initiating proinflammatory cytokine/chemokine cas-
cades seen in the setting of CKD and end-stage renal disease.4 
Thus, it has been hypothesized that gut-microbiota–derived 
uremic toxins may serve as both therapeutic targets and assess-
ment tools for renal diseases in this vulnerable population.1,5–7 
However, demonstration of a role for specific uremic toxins in 
CVD pathogenesis has been indirect.
Our group recently identified a novel mechanistic link be-
tween gut microbiota metabolism of dietary trimethylamine-
containing nutrients and CVD pathogenesis.8–13 Specifically, 
gut microbiota–mediated metabolism of phosphatidylcholine, 
choline, or L-carnitine each have been shown to produced tri-
methylamine-N-oxide (TMAO), and in multiple clinical studies, 
TMAO levels have been shown to be associated with cardio-
vascular risks.8–10,13 Furthermore, animal model studies have 
revealed that TMAO is mechanistically linked to atherosclero-
sis development through multiple distinct pathways.8,14 Animal 
model and human clinical studies demonstrate an obligatory role 
for gut microbiota in TMAO formation from TMA-containing 
nutrients, including choline and phosphatidylcholine,9,10 L-
carnitine,8 and more recently, γ-butyrobetaine,15 and to a lesser 
degree, the choline oxidation metabolite betaine.11
TMAO is cleared by the kidney, and previous studies have 
reported that TMAO is elevated in subjects with impaired renal 
function.16–18 It is thus an attractive hypothesis that TMAO may 
represent an excellent mechanism-based marker of CVD risk 
in subjects with impaired renal function. In one large study of 
subjects with predominantly preserved renal function, we re-
ported the prognostic value of TMAO for predicting 3-year risk 
for major adverse cardiovascular events (myocardial infarction, 
stroke, or death) remained significant after adjustments for re-
nal function.9 However, no studies to date have directly looked 
at the long-term mortality risk of TMAO among CKD subjects. 
Interestingly, plasma TMAO levels in apparently healthy do-
nors was identified in a prospective multicenter study aimed at 
identifying donor factors associated with delayed graft func-
tion in renal transplant recipients.19 A direct role for TMAO in 
affecting renal functional impairment has not been reported. 
Herein, we sought to examine both the prognostic value of 
TMAO among CKD subjects and the potential contribution of 
dietary-induced, gut microbiota–associated TMAO formation 
in the development and progression of CKD.
Methods
Human Studies
This is a single-center, prospective cohort study approved by the 
Cleveland Clinic Institutional Review Board. We included adult 
subjects (aged, ≥18 years) who underwent elective diagnostic cor-
onary angiography for cardiac evaluation at our institution from 
2001 to 2007 as previously described.9 We excluded subjects with 
known acute coronary syndromes or revascularization procedures 
within 30 days of enrollment or history of congenital heart disease. 
After informed consent, fasting plasma blood samples were col-
lected using ethylenediaminetetraacetic acid tubes before any drug 
administration via the arterial sheath, and immediately processed 
and frozen in −80ºC until analysis. Estimated glomerular filtra-
tion rate (eGFR) was calculated according to the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) creatinine and 
cystatin C formula,20 with CKD defined as eGFR <60 mL/min per 
1.73 m2 (CKD stage 3 or beyond). Ascertainment of all-cause mor-
tality at 5 years was performed by prospective telephone contact 
and chart review plus interrogation of the Social Security Death 
Index (up to 2011).
Plasma Analysis
Trimethylamine-N-oxide (TMAO) levels were determined by stable 
isotope dilution high-performance liquid chromatography with on-
line electrospray ionization tandem mass spectrometry on an AB 
SCIEX 5500 triple quadrupole mass spectrometer (AB SCIEX; 
Framingham MA) using d9-(trimethyl)–labeled internal standards 
as previously described.10,21 High-sensitivity C-reactive protein 
(hsCRP), fasting lipid panel, cystatin C, and serum creatinine were 
measured using the Architect ci8200 platform (Abbott Laboratories, 
Abbott Park, IL).
Animal Study
To test for a potential contribution of dietary choline or TMAO to 
promotion of renal dysfunction directly, C57BL6J mice were fed 
with the following diets for 6 weeks: (1) a chemically defined diet 
comparable in composition with standard chow diet (Teklad 2018; 
Harland Laboratories) that contains 0.08% (g/g) total choline; (2) the 
same diet supplemented with choline (1.0% total); and (3) the same 
diet supplemented with TMAO (0.12%). A separate study included 
C57BL6J mice with ApoE−/− background fed with the same diet 
groups for comparing their cystatin C levels at 14 weeks of follow-
up using a commercially available mouse ELISA (R&D systems, 
Minneapolis MN). This study has been approved by the Cleveland 
Clinic Institutional Animal Care and Use Committee.
Quantitative Histological Techniques
Mason trichome staining was performed on deparafinized 5-µm 
serial kidney sections. The kidney sections were mounted under 
a Leica DM 2500 microscope and digitized with a QImaging 
MicroPublisher 5.0 RTV camera for wide field microscopy. 
Quantitative morphometric analysis was performed on cortical 
fields (≥8 from each animal) lacking major blood vessels, and the 
collagen volume was determined using automated (for batch anal-
ysis) and customized algorithms/scripts (ImageIQ Inc, Cleveland, 
OH) written for Image Pro Plus 7.0. Briefly, a set of representa-
tive images are chosen that demonstrated a wide range of staining 
intensities and prevalence. In an automated script, these training 
images were loaded one after another prompting the user to delin-
eate blue pixels representing positive collagen staining using an 
interactive color picking tool. An iterative color profile or clas-
sifier was generated and subsequently applied to all images in a 
given directory using a fully automated algorithm. Positive pixels, 
as defined by the color profile, were segmented and summed to 
provide positive staining area. Total tissue area was determined 
by extracting the saturation channel, applying a low-pass filter, 
and thresholding the result. Any area within the general tissue 
boundary that was empty (ie, white) was removed by converting 
the original image to grayscale and applying a fixed threshold 
for nonbackground pixels on adequately white-balanced images. 
Finally, total tissue area and total stained area were exported to 
Excel. For postprocessing verification, segmented regions were 
superimposed onto the original image (green outlines) and saved 
for each image analyzed.
Nonstandard Abbreviations and Acronyms
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
eGFR estimated glomerular filtration rate
HR hazard ratio
hsCRP high-sensitivity C-reactive protein
TMAO trimethylamine-N-oxide
Preparation of Tissue Homogenates and 
Immunoblotting
Equal amounts of protein were prepared using standard biochemi-
cal methods and subjected to SDS-PAGE and electrotransfer 
of proteins from gels to Immobilon-P membranes (Millipore). 
Membranes were incubated with the following antibodies: SMAD3 
and phospho-SMAD-3(Ser423/425; Cell Signaling Technology); 
tubulin (Santa Cruz Biotechnology); kidney injury molecular 1 
(Novus Biologicals). Detection of all immunoblots was performed 
with the SNAP i.d. Protein Detection System (Millipore) and 
Super Signal Chemiluminescent Substrate Products (Pierce), and 
band intensity was analyzed by densitometry (ImageQuant; GE 
Healthcare).
Statistical Analyses
Continuous variables were summarized as mean±SD if normally 
distributed and median (interquartile range) if non-normally distrib-
uted. The Student t test or Wilcoxon rank-sum test for continuous 
variables and χ2 test for categorical variables were used to exam-
ine the difference between groups. Spearman correlation was used 
to examine the associations between TMAO and other laboratory 
measurements. Kaplan–Meier survival plots and Cox proportion-
al hazards analysis were used to determine hazard ratio (HR) and 
95% confidence intervals (95% CI) for all-cause mortality strati-
fied according to TMAO in quartiles. Adjustments were made for 
individual traditional risk factors, including age, sex, systolic blood 
pressure, low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, smoking, diabetes mellitus, and log-transformed 
hsCRP to predict all-cause mortality risks. Additional adjustment 
for log-transformed eGFR was also performed. Net reclassifica-
tion and area under receiver operator characteristic curve were 
calculated according to mortality risk estimated using Cox models 
adjusted for above-mentioned traditional risk factors with versus 
without TMAO as previously described.22 All analyses performed 
used R 2.15.1 (Vienna, Austria). P<0.05 was considered statistically 
significant.
Results
Elevated TMAO in Patients With Renal 
Insufficiency Portend Poorer Survival
Baseline clinical and laboratory characteristics of the cohort 
are reported in Table 1. A total of 3687 subjects were included 
in this analysis, among which 521 subjects fulfilled criteria 
for CKD and 3166 subjects for non-CKD. When compared 
with non-CKD subjects, TMAO levels were elevated in pa-
tients with CKD (median TMAO, 7.9 [interquartile range, 
5.2–12.4] versus 3.4 [interquartile range 2.3–5.3] μmol/L; 
P<0.001; Figure 1A). In the CKD cohort, TMAO modestly 
correlated with eGFR (r=−0.48; P<0.001) and cystatin C 
(r=0.46; P<0.001), but did not correlate with hsCRP (r=0.04; 
P=0.332).
In the CKD cohort, higher TMAO levels (quartiles 4 ver-
sus 1) were associated with a 2.8-fold increase in risk for 
all-cause mortality at 5 years (unadjusted HR, 2.76; 95% 
CI, 1.74–4.37; P<0.001). After adjusting for traditional 
CVD risk factors, log-transformed hsCRP, and log-trans-
formed eGFR, higher TMAO levels still were associated 
with a 1.9-fold poorer 5-year survival (adjusted HR, 1.93; 
95% CI, 1.13–3.29; P<0.05; Table 2; Kaplan–Meier curve 
shown in Figure 1B). When stratified according to median 
levels (7.9 μmol/L), higher TMAO conferred a 1.7-fold in-
crease in risk for all-cause mortality (HR, 1.70; 95% CI, 
1.25–2.30; P<0.001) and remained significant after adjust-
ing for traditional risk factors and log-transformed hsCRP 
Table 1. Baseline Characteristics
Characteristic
Non-CKD Cohort
eGFR≥60 
(n=3,166)
CKD Cohort 
eGFR<60
(n=521) P Value
Age, y 62±11 70±10 <0.001
Men, % 66 48 <0.001
Diabetes mellitus, % 27 53 <0.001
Hypertension, % 69 88 <0.001
Smoking, % 66 61 0.047
History of MI, % 40 53 <0.001
History of stroke, % 5 13 <0.001
History of CABG, % 28 42 <0.001
History of PCI, % 31 30 0.728
LDL, mg/dL 97 (79–118) 93 (72–114) <0.001
HDL, mg/dL 34 (28–41) 32 (26–40) <0.001
hsCRP, mg/dL 2.2 (0.9–5.0) 4.1 (1.8–9.6) <0.001
eGFR, mL/min per 1.73 m2 89 (78–101) 49 (38–55) <0.001
Cystatin C, mg/L 0.9 (0.8–1) 1.5 (1.3–1.8) <0.001
ACE inhibitor/ARB, % 48 66 <0.001
Statins, % 61 59 0.437
β-blockers, % 63 68 0.04
Aspirin, % 75 67 <0.001
TMAO, μmol/L 3.4 (2.3–5.3) 7.9 (5.2–12.4) <0.001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; eGFR, 
estimated glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-
sensitivity C-reactive protein; LDL, low-density lipoprotein; MI, myocardial infarction; 
PCI, percutaneous coronary intervention; and TMAO, trimethylamine-N-oxide.
Expressed as % or median (interquartile ranges), except for age as mean±SD.
Figure 1. Prognostic Value of plasma 
trimethylamine N-oxide (TMAO) levels 
in the chronic kidney disease (CKD) 
Cohort. In a cohort of stable patients 
undergoing elective diagnostic coronary 
evaluation, subjects with underlying CKD 
Stage 3+ (n=521) demonstrated higher 
levels of fasting plasma TMAO than 
those with no CKD (n=3,166; P<0.01; A). 
Increasing quartiles fasting plasma TMAO 
levels portend increased risk for all-cause 
mortality at 5 years in patients with CKD 
(n=521; B).
(adjusted HR, 1.72; 95% CI, 1.16–2.34; P<0.001), as well 
as with addition of cystatin C to the model (adjusted HR, 
1.45; 95% CI, 1.05–2.02; P<0.05). Using median cohort 
cutoffs with low cystatin C (<1.4 mg/dL) and low TMAO 
(<7.9 μmol/L) as reference, those with concomitant high 
cystatin C and high TMAO had a 3-fold increase in mortal-
ity risk (HR, 3.01; 95% CI, 1.97–4.59; P<0.001). These 
findings are consistent with the notion that elevated TMAO 
is associated with poor prognosis in patients with estab-
lished CKD.
Increased TMAO Levels in Non-CKD Patients With 
Elevated Cystatin C
Within the non-CKD cohort (n=3166), the prognostic value 
of elevated TMAO (quartile 4 versus 1) remained predic-
tive of 5-year mortality risk (HR, 2.21; 95% CI, 1.57–3.12; 
P<0.001), as well as after adjusting for traditional risk fac-
tors, log-transformed hsCRP, and log-transformed eGFR 
(adjusted HR, 1.47; 95% CI, 1.02–2.12; P<0.05; Table 2). 
These findings were similar when restricted to subjects with 
preserved eGFR (≥60 mL/min per 1.73 m2) plus normal cys-
tatin C (<1.4 mg/dL; n=3151). Elevated TMAO levels are 
associated with higher 5-year mortality risk among subjects 
with either normal or elevated cystatin C levels (Figure 2). 
Using median cohort cutoffs with low cystatin C (<0.9 mg/
dL) and low TMAO (<3.4 μmol/L) as reference, those with 
concomitant high cystatin C and high TMAO had a 3.7-fold 
increase in mortality risk (HR, 3.67; 95% CI, 2.57–5.23; 
P<0.001).
Dietary Choline and Dietary TMAO Both Promote 
Renal Fibrosis and Dysfunction in Animal Models
To directly test the hypotheses that either dietary TMAO 
itself, or dietary nutrients that contribute to gut microbiota–
dependent production of TMAO, can affect development and 
progression of CKD, we performed animal model studies. 
Conventionally housed 8-week-old male mice (C57BL/6J 
background) were fed ad libitum a chemically defined diet 
comparable with normal chow (0.08% choline) or the same 
diet supplemented with either choline (1.0% final) or TMAO 
(0.12%), as described under Methods section of this article. 
After 6 weeks, we observed significant (P<0.01) increases 
in TMAO levels in both the TMAO-supplemented and the 
choline-supplemented groups of mice (Figure 3A), with 
TMAO levels observed within the range of values detected 
among CKD subjects studied (97.5 percentile 77.6 μmol/L, 
99 percentile 96.3 μmol/L). Importantly, elevated TMAO 
levels were associated with corresponding increases in tu-
bulointerstitital fibrosis and collagen deposition (Figure 3B 
and 3C) and phosphorylation of Smad3, an important 
regulator of the profibrotic transforming growth factor-β/
Smad3 signaling pathway during fibrotic kidney disease23 
(Figure 3D). Furthermore, TMAO-fed and choline-fed mice 
experienced increased kidney injury marker-1 (Figure 4A 
and 4B). Extending the TMAO/choline feeding to 16 weeks 
Table 2. Cox Proportional Hazards Analysis of Plasma TMAO Levels Stratified by Quartile 
in Predicting Risk of All-Cause Mortality at 5 Years: CKD and Non-CKD Cohorts
TMAO (Range)
Quartile 1 Quartile 2 Quartile 3 Quartile 4
CKD cohort (n=521)
 Range, μmol/L <5.2 5.2–7.9 7.9–12.4 ≥12.4
 Events 26/129 (20.2%) 42/131 (32.1%) 43/130 (33.1%) 63/131 (48.1%)
 Unadjusted HR 1 1.70 (1.04–2.79)* 1.75 (1.07–2.87)* 2.76 (1.74–4.37)†
 Adjusted HR 1 1.42 (0.85–2.35) 1.51 (0.90–2.51) 1.93 (1.13–3.29)*
Non-CKD cohort (n=3166)
 Range, mmol/L <2.3 2.3–3.4 3.4–5.3 ≥5.3
 Events 48/787 (6.1%) 59/793 (7.4%) 81/791 (10.2%) 104/795 (13.1%)
 Unadjusted HR 1 1.22 (0.83–1.79) 1.70 (1.19–2.43)† 2.21 (1.57–3.12)†
 Adjusted HR 1 1.08 (0.74–1.58) 1.23 (0.84–1.78) 1.47 (1.02–2.12)*
Adjusted model: adjusted for traditional risk factors (age, sex, systolic blood pressure, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, smoking, and diabetes mellitus), log(high-sensitivity C-reactive 
protein), and log(estimated glomerular filtration rate). Events expressed as n (%), HR expressed as HR (95% 
confidence interval). CKD indicates chronic kidney disease; HR, hazard ratio; and TMAO, trimethylamine-N-oxide.
*P<0.05.
†P<0.001.
Figure 2. Comparative prognostic value of plasma 
trimethylamine-N-oxide (TMAO) and Cystatin C (CysC) in 
the non-chronic kidney disease (CKD) cohort. Subjects with 
elevated CysC (≥0.9 mg/dL) and TMAO (≥3.4 μmol/L) had the 
highest 5-year mortality risk in this non-CKD cohort (n=3188).
was associated with increased serum cystatin C levels com-
pared with chow-fed mice (Figure 4C). On further exami-
nation, striking dose-dependent relationships were noted 
between plasma TMAO levels and monitored indices of 
renal histopathologic (Figure 3C and 3D) and functional 
impairment (Figure 4B).
Discussion
There are several key findings in this report. First, we ob-
served in subjects with CKD that TMAO levels are not only 
elevated when compared with non-CKD subjects but also 
portend poorer overall survival. Second, we observed that 
within the non-CKD cohort, higher levels of TMAO portend 
poorer survival both within the cohort of low levels and high 
levels of cystatin C (stratified at median levels). Interestingly, 
the prognostic value for the highest TMAO quartile in pre-
dicting future mortality risk in this cohort remained robust 
even after adjustment for traditional risk factors. Third, ex-
tending to animal models studies, dietary exposure of either 
choline or TMAO lead to the development of renal tubuloin-
terstitial fibrosis and early measures of dysfunction (elevated 
cystatin C). These studies thus suggest both a causal relation-
ship and clinical relevance of dietary choline-induced, gut 
 microbiota–mediated, TMAO formation in CKD develop-
ment and progression.
TMAO is a low molecular weight compound that is easily 
filtered by the kidney and effectively removed by hemodialy-
sis.16 Considered a nitrogenous waste product whose levels 
rise with diminished renal function, elevated TMAO levels 
have been reported in small cohorts (n<20) of subjects with 
either end-stage renal disease or CKD, where levels were 
shown to correlate with both serum urea and creatinine.18 
Detailed animal and human experiments on the renal clear-
ance of methylamines, such as TMA and TMAO, have been 
performed and confirm the kidneys as the primary elimina-
tion route.24 Interestingly, the urinary clearances of both TMA 
and TMAO are higher than the glomerular filtration rate, and 
TMAO clearance also decreases with increasing dose, which 
suggests that saturable renal tubular secretion occurs.25 The 
majority of a dose of TMA is also excreted in the urine, with 
varying proportions in the forms of TMA and TMAO be-
ing dependent on the dose level.26 Urinary TMAO levels are 
Figure 3. Dietary choline/trimethylamine-N-oxide (TMAO) exposure contributes to progressive renal fibrosis in murine model. 
Plasma TMAO (A) levels are increased after 6 week feeding TMAO (0.12%), or Choline (1.0%) diets vs Chow (0.08% choline) fed mice. 
Representative Mason trichrome histology (B) quantitative morphometry and its relationship with TMAO levels (C), and SMAD3 activation 
by phosphorylation at serine 423/425 (D) and its relationship with TMAO levels (E) in mouse kidneys after 6 week feeding of Chow (0.08% 
choline), TMAO (0.12%), and Choline (1.0%) diets. Scale bar, 100 um. **P<0.01 vs Chow, n≥5 mice per group.
Figure 4. Dietary choline/trimethylamine-N-oxide (TMAO) exposure contributes to progressive renal injury and dysfunction in 
murine model. Immunoblot of kidney injury molecular 1 (KIM-1) expression (A) and its relationship with TMAO levels (B) in mouse kidneys 
after 6 week feeding of chow (0.08% choline), TMAO (0.12%), and choline (1.0%) diets. Also shown are plasma cystatin C levels (C) after 
16 week feeding of Chow, TMAO (0.12%), and Choline (1.0%) diets. **P<0.01 vs Chow, n≥5 mice per group.
reported to rise with episodes of kidney graft dysfunction in 
renal transplant recipients, suggesting an intrinsic accumula-
tion of TMAO (presumably as an osmolyte like urea) that is 
released during damage of the renal medullary cells.27–30 The 
link between elevated TMAO and adverse prognosis in CKD, 
and even in the setting of subclinical renal insufficiency (el-
evated cystatin C in non-CKD patients) observed in our study 
is consistent with the heightened risk of developing CVD in 
the CKD population.
Our results from animal studies showed for the first time 
a direct mechanistic link between dietary choline, or di-
etary TMAO, and progressive renal dysfunction, even in 
the C57BL/6J mouse model that is known to be relatively 
resistant to renal injury.31 Indeed, exposure to either a high 
choline diet or a diet supplemented directly with TMAO 
both led to increased levels of the early kidney injury 
molecular 1 and enhanced phosphorylation of Smad3, an 
important regulator of renal fibrosis.32 A more prolonged 
exposure to either the high choline diet or the TMAO-
supplemented diet both led to increased plasma levels of 
cystatin C, a sensitive indicator of renal functional im-
pairment. Importantly, the plasma TMAO levels observed 
within the animal models on either choline or TMAO-
supplemented diets were within the range of TMAO lev-
els observed among subjects with CKD. Furthermore, 
examining TMAO levels as a continuous variable, a dose-
dependent relationship between plasma TMAO levels and 
mortality risk was observed (log[TMAO]: adjusted HR, 
1.41; 95% CI, 1.23–1.61; P<0.001 for CKD cohort; ad-
justed HR, 1.21; 95% CI, 1.07–1.36; P<0.01 for non-CKD 
cohort). Although there is the appearance of a threshold 
level of TMAO that is associated with increased risk with 
the predicted outcomes using quartile-based analyses in 
the current sized study, the biological data collected in the 
animal model studies (scatter plots comparing TMAO lev-
els versus the CKD-related phenotypes) show a continu-
ous dose-dependent relationship between TMAO levels 
and renal tubulointerstitial fibrosis (pSMAD3, and vari-
ous measures of collagen or fibrosis), and renal functional 
impairment (cystatin C). Interestingly, a recent untargeted 
metabolomic study from the Framingham Heart Study 
among subjects with normal renal function identified el-
evated choline and TMAO levels at baseline were each 
associated with an increased future risk of developing 
CKD.33 Our animal model findings, therefore, provide a 
potential mechanistic rationale for the Framingham obser-
vational data, and collectively, further link elevated sys-
temic TMAO levels with increased susceptibility for the 
development of CKD.
The prospects that exposure to specific dietary nutrients, such 
as choline, phosphatidylcholine (lecithin), and L-carnitine via 
gut microbiota may affect susceptibility to the development 
and progression of both CKD and CVD has important poten-
tial public health implications. Randomized nutritional inter-
vention studies in patients with CKD to date have not explored 
a potential role for choline, phosphatidylcholine, L-carnitine, 
or TMAO (which can be abundant in certain types of fish) 
in disease progression. Similarly, epidemiological studies are 
rather limited on the topic of diet and CKD risks, even though 
a recommended renal diet is typically low in protein intake. 
Dietary management of patients with CKD represents a chal-
lenge, and much less is known about nutritional factors that 
might predispose to enhanced risk for development of CKD or 
its progression. Interestingly, in a substudy (n=3296) among 
women who had urine microalbumin levels available from 
the Nurses Health Study, ≥2 servings of red meat (primary 
dietary source of L-carnitine) per week were directly associ-
ated with enhanced risk for development of microalbuminuria 
(odds ratio, 1.51; 95% CI, 1.01–2.26).34 Further investigations 
in dietary predisposition to CKD development and progres-
sion are warranted. On the basis of the present studies, we 
conclude that a diet monitored by following TMAO levels and 
designed to limit TMAO precursors (low in red meat, meats, 
liver, egg yolk, and high fat dairy products) and TMAO itself 
(certain fish) would be an attractive diet to test to see whether 
it reduces the rate of CKD progression. However, it is impor-
tant to note that choline is an essential nutrient; therefore, its 
total elimination from the diet is ill advised and could result in 
development of a deficiency state.35
Collectively, the present data indicate a dietary-induced, 
intestinal microbiota-dependent mechanism may contribute 
to both progressive renal fibrosis and dysfunction, and mor-
tality risks, among subjects with CKD. They also build on 
the recent body of evidence demonstrating a mechanistic link 
between gut microbiota–associated metabolic dysregulation 
and cardiovascular risk in humans.8–12 The discovery of the 
metaorganismal pathway involved in TMAO generation thus 
affords a unique opportunity to investigate systematically the 
potential contributions of discrete participants in the overall 
diet → microbe → host enzyme pathways for TMAO forma-
tion and development and progression of cardiorenal dysfunc-
tion. It is interesting that in both animal models and patients 
with established CKD, pre- and probiotic intervention studies 
have been performed, with reports of changes in gut micro-
biota composition and activity. For example, Lactobacillus 
acidophilus or bifidobacterium has been reported to reduce 
inflammatory signaling associated with the microbiota-de-
rived metabolites that accumulate in CKD,36–39 in addition to 
improving renal function modestly.40,41 Similarly, prebiotic 
compound use to interrupt pathways that lead to gut micro-
biota–derived uremic toxins, such as indoxyl sulfate and p-
cresyl sulfate, has shown some efficacy in both human and 
animal trials of CKD.5,42 Additonal studies are warranted to 
see whether dietary interventions, or disruption of the meta-
organismal pathway involving TMAO production, may retard 
the development of CKD, progression of renal functional im-
pairment among subjects with CKD, and adverse CVD event 
risks in subjects with CKD.
Conclusions
The gut microbiota–dependent product, TMAO, is associated 
with both higher risk of progressive renal fibrosis and func-
tional impairment, and poorer long-term survival.
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